jnj-q2 jnj-q2 jnj-q2 is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. specifically, jnj-q2 is being actively studied for treatment of methicillin-resistant staphylococcus aureus (mrsa) infections. jnj-q2clinical dataroutes ofadministrationoral, ividentifiers iupac name 7--1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid cas number878592-87-1 ychemspider9721013 nunii070sv15rjacomptox dashboard (epa)dtxsid20236667 chemical and physical dataformulac21h23f2n3o4molar mass419.429 g·mol−13d model (jsmol)interactive image smiles fc1c(c(oc)c2c(c1)c(=o)c(\c(=o)o)=c/n2c3cc3)n4c/c(=c(/f)cn)ccc4 inchi inchi=inchi=1s/c21h23f2n3o4/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12h,2-6,8-9,24h2,1h3,(h,28,29)/b16-11+ nkey:vmkvdaafmqkzjs-lfibnoncsa-n n furiex pharmaceuticals has licensed jnj-q2 from janssen pharmaceutica, a unit of johnson & johnson, which discovered jnj-q2. furiex is responsible for its development and commercialization. both oral and intravenous formulations are being developed. as of 2016, tests are ongoing.